Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1958 1
1960 1
1966 1
1967 1
1971 1
1972 2
1973 2
1974 3
1975 2
1976 2
1977 2
1978 6
1979 4
1980 7
1981 9
1982 6
1983 2
1984 2
1985 5
1986 1
1987 5
1988 7
1989 4
1990 6
1991 12
1992 7
1993 9
1994 11
1995 16
1996 25
1997 17
1998 20
1999 15
2000 10
2001 15
2002 8
2003 17
2004 16
2005 17
2006 17
2007 8
2008 14
2009 30
2010 30
2011 38
2012 35
2013 35
2014 43
2015 46
2016 36
2017 35
2018 36
2019 26
2020 30
2021 22
Text availability
Article attribute
Article type
Publication date

Search Results

726 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacotherapy of Zollinger-Ellison syndrome.
Ito T, Igarashi H, Uehara H, Jensen RT. Ito T, et al. Among authors: uehara h. Expert Opin Pharmacother. 2013 Feb;14(3):307-21. doi: 10.1517/14656566.2013.767332. Epub 2013 Jan 30. Expert Opin Pharmacother. 2013. PMID: 23363383 Free PMC article. Review.
RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y. Takeuchi K, et al. Among authors: uehara h. Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658. Nat Med. 2012. PMID: 22327623
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. Taniguchi H, et al. Among authors: uehara h. Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0. Nat Commun. 2019. PMID: 30651547 Free PMC article.
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Wang R, et al. Among authors: uehara h. Nat Commun. 2020 Sep 14;11(1):4607. doi: 10.1038/s41467-020-18442-4. Nat Commun. 2020. PMID: 32929081 Free PMC article.
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. Okura N, et al. Among authors: uehara h. Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17. Clin Cancer Res. 2020. PMID: 31953310 Free article.
Chronic Dicer1 deficiency promotes atrophic and neovascular outer retinal pathologies in mice.
Wright CB, Uehara H, Kim Y, Yasuma T, Yasuma R, Hirahara S, Makin RD, Apicella I, Pereira F, Nagasaka Y, Narendran S, Fukuda S, Albuquerque R, Fowler BJ, Bastos-Carvalho A, Georgel P, Hatada I, Chang B, Kerur N, Ambati BK, Ambati J, Gelfand BD. Wright CB, et al. Among authors: uehara h. Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2579-2587. doi: 10.1073/pnas.1909761117. Epub 2020 Jan 21. Proc Natl Acad Sci U S A. 2020. PMID: 31964819 Free PMC article.
726 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page